AXNXIndustrials · Engineering & ConstructionTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 12 of 100 as at 4 Nov 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Axonex AI Group Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (93): Smaller than most of the companies we track.
Growth (6): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on AXNX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Nov 2024 | Needham | Reiterates | Hold | — |
| 5 Aug 2024 | Needham | Reiterates | Hold | — |
| 6 May 2024 | Needham | Reiterates | Hold | — |
| 29 Feb 2024 | RBC Capital | Reiterates | Sector Perform | — |
| 17 Jan 2024 | Needham | Downgrade | Hold | — |
| 16 Jan 2024 | Truist Securities | Downgrade | Hold | — |
| 12 Jan 2024 | CL King | Downgrade | Neutral | — |
| 12 Jan 2024 | Leerink Partners | Downgrade | Market Perform | — |
| 12 Jan 2024 | Piper Sandler | Downgrade | Neutral | — |
| 12 Jan 2024 | Truist Securities | Downgrade | Hold | — |
| 10 Jan 2024 | Wells Fargo | Downgrade | Equal-Weight | — |
| 9 Jan 2024 | Wolfe Research | Downgrade | Peer Perform | — |
| 22 Dec 2023 | Truist Securities | Maintains | Buy | — |
| 31 Oct 2023 | Morgan Stanley | Maintains | Overweight | — |
| 31 Oct 2023 | Needham | Maintains | Buy | — |
| 31 Oct 2023 | Piper Sandler | Maintains | Overweight | — |
| 16 Oct 2023 | Leerink Partners | Initiates | Outperform | — |
| 28 July 2023 | Baird | Maintains | Outperform | — |
| 28 July 2023 | Keybanc | Maintains | Overweight | — |
| 28 July 2023 | Needham | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
AXNX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Axonex AI Group Ltd. returned −94.4% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 93% of US stocks
Cheaper than 44% of US stocks
Cheaper than 87% of US stocks
Cheaper than 64% of US stocks
Higher than 8% of US stocks
Higher than 89% of US stocks
Higher than 13% of US stocks
Higher than 98% of US stocks
Higher than 6% of US stocks
Higher than 3% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Axonex AI Group Ltd. has a market value of $5.9M and an enterprise value of $2.7M.
Revenue in the twelve months to 30 Sept 2024: $431.9M. The latest quarter shrank 32.4% year on year.
Net income over the same four quarters: −$5.7M, a −1.3% net margin.
Diluted earnings per share, trailing twelve months: $−0.12.
Free cash flow in the twelve months to 30 Sept 2024: $5.4M, after $8.9M of capital spending.
Trailing P/E: −8.5×; forward P/E: 83.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Axonex AI Group Ltd. employs 36 people — $12.0M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Axonex AI Group Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Axonex AI Group announced a 2-for-5 reverse stock split covering all issued and unissued Class A and Class B ordinary shares. The company’s board approved the split on October 2, 2026.
Why it matters — AXNX watchers may wish to note the announced change to the company’s ordinary-share structure.
Axonex AI Group said its indirect majority-owned joint venture, Rice Robotics (Hong Kong) Limited, joined FLAIR’s Embodied AI International Applications Hub as one of its first technology partners. The announcement also identifies the launch of education humanoid TOMO.
Why it matters — The announcement highlights a partnership and a humanoid-robot launch tied to Axonex AI’s embodied AI business, including potential applications in education and manufacturing.
Formerly Mint Incorporation Limited (NASDAQ: MIMI), the company announced a new corporate identity as Axonex AI Group Limited and a new ticker, NASDAQ: AXNX. It said the changes reflect its strategic focus on AI and robotics as its primary growth engine.
Why it matters — MIMI watchers should note the company's announced identity and ticker change alongside its stated strategic focus on AI and robotics.
Mint said its majority-owned subsidiary Axonex Robotics entered a two-year OEM supply and license agreement with Ireland-based Centridex. The programme has a potential value of approximately €3 million, with an initial order package worth approximately €450,000 for robot kits and platform licensing.
Why it matters — The agreement adds a European customer relationship and an initial order to Mint’s robotics business.
Mint Incorporation Limited announced that its indirect majority-owned subsidiary Rice AI has entered into a licensing agreement with Pudgy Penguins to develop and commercialize a co-branded "Blue Pengu Minibot," a limited-edition AI-powered companion robot featuring the Pudgy Penguins character.
Why it matters — This licensing partnership expands Mint's AI robotics product line into the Web3 consumer space, potentially widening its market reach through a well-recognized brand.
Of the 5 analysts covering Axonex AI Group Ltd., 1 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Axonex AI Group Ltd. 12 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Axonex AI Group Ltd. ranks 12 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).
No analyst covering Axonex AI Group Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AXNX are extrapolating price history, which says nothing about the business.
Axonex AI Group Ltd. returned -94.4% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Axonics, Inc. is a medical technology company that develops and commercializes minimally invasive products for adults with bladder and bowel dysfunction.
The most recent item we track (GlobeNewsWire, 20 Oct 2026): "Axonex AI Group Limited Announces 2-for-5 Reverse Stock Split". Axonex AI Group announced a 2-for-5 reverse stock split covering all issued and unissued Class A and Class B ordinary shares. The company’s board approved the split on October 2, 2026.
Axonics, Inc. is a medical technology company that develops and commercializes minimally invasive products for adults with bladder and bowel dysfunction. Its portfolio includes implantable sacral neuromodulation systems designed to deliver mild electrical stimulation to targeted sacral nerves, supporting the treatment of overactive bladder, urinary urgency and frequency, urinary urge incontinence, non-obstructive urinary retention, and fecal incontinence. The company offers both rechargeable and recharge-free system configurations, addressing different clinical and patient needs. Axonics, Inc. also provides Bulkamid, a urethral bulking agent used to treat female stress urinary incontinence. Through its focus on urology, urogynecology, and pelvic health, the company serves healthcare providers and patients seeking alternatives to medication or more invasive procedures. Its products occupy a specialized role within the medical device market by applying neuromodulation and injectable therapies to persistent urinary and bowel conditions, helping broaden treatment options across related areas of functional pelvic medicine.
CEO Mr. Hoi Lung Chan · 36 employees · Hong Kong · https://mimintinc.com
